NASDAQ:INGN Inogen (INGN) Stock Forecast, Price & News $10.68 -0.48 (-4.30%) (As of 05:22 PM ET) Add Compare Share Share Today's Range$10.63▼$11.1350-Day Range$10.01▼$13.8652-Week Range$9.88▼$32.01Volume306,095 shsAverage Volume270,370 shsMarket Capitalization$246.93 millionP/E RatioN/ADividend YieldN/APrice Target$24.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Inogen MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside124.7% Upside$24.00 Price TargetShort InterestBearish5.15% of Shares Sold ShortDividend StrengthN/ASustainability-1.12Upright™ Environmental ScoreNews Sentiment0.91Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.16) to ($1.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.13 out of 5 starsMedical Sector363rd out of 981 stocksSurgical Appliances & Supplies Industry9th out of 18 stocks 3.2 Analyst's Opinion Consensus RatingInogen has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.00, Inogen has a forecasted upside of 124.7% from its current price of $10.68.Amount of Analyst CoverageInogen has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.15% of the outstanding shares of Inogen have been sold short.Short Interest Ratio / Days to CoverInogen has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Inogen has recently increased by 0.85%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldInogen does not currently pay a dividend.Dividend GrowthInogen does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInogen has received a 51.98% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Medical ventilators" product. See details.Environmental SustainabilityThe Environmental Impact score for Inogen is -1.12. Previous Next 2.7 News and Social Media Coverage News SentimentInogen has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Inogen this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 1 people have added Inogen to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Inogen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.64% of the stock of Inogen is held by insiders.Percentage Held by Institutions95.93% of the stock of Inogen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Inogen are expected to grow in the coming year, from ($2.16) to ($1.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Inogen is -2.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inogen is -2.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInogen has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Inogen (NASDAQ:INGN) StockInogen, Inc. is a medical technology company, which engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its products include Inogen One G4 system, Inogen One G3 system, Inogen One G5 system, Inogen TAV, and Inogen at Home. The company was founded by Alison Perry, Alison K. Bauerlein, Brenton Taylor, and Byron Myers on November 27, 2001 and is headquartered in Goleta, CA.Read More Receive INGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inogen and its competitors with MarketBeat's FREE daily newsletter. Email Address INGN Stock News HeadlinesJune 7, 2023 | finanznachrichten.deInogen Alliance: Understanding Environmental Contaminants: A Primer for BusinessesMay 16, 2023 | finance.yahoo.comWill the Current Downturn Affect Inogen (INGN)?June 8, 2023 | Altimetry (Ad)Pentagon Consultant—Here's how Biden Wins Landslide Re-election—but also hand Joe Biden a landslide re-election win. What would America look like if we slide further towards Socialism? Full story and 4 steps you can take,May 15, 2023 | finance.yahoo.comInogen to Present at 43rd Annual William Blair Growth Stock ConferenceMay 13, 2023 | americanbankingnews.comInogen (NASDAQ:INGN) Downgraded by StockNews.com to SellMay 5, 2023 | finance.yahoo.comInogen (INGN) Q1 Earnings Beat Estimates, Revenues LagMay 5, 2023 | americanbankingnews.comInogen (NASDAQ:INGN) Upgraded to "Hold" at StockNews.comMay 4, 2023 | finance.yahoo.comInogen (INGN) Reports Q1 Loss, Lags Revenue EstimatesJune 8, 2023 | Behind the Markets (Ad)BREAKING: The truth about war with ChinaForeign Affairs reports, "China is Now in a Prewar Tempo of Political and Military Preparations." China has one goal: take control of Taiwan, and an invasion could happen any day. I've identified 5 investments I believe are in immediate danger. But you can get out of them now - before it's too late.May 4, 2023 | finance.yahoo.comHere's What Key Metrics Tell Us About Inogen (INGN) Q1 EarningsMay 4, 2023 | finance.yahoo.comInogen Announces First Quarter 2023 Financial ResultsMay 2, 2023 | americanbankingnews.comInogen (INGN) Scheduled to Post Earnings on ThursdayApril 29, 2023 | americanbankingnews.comInogen (NASDAQ:INGN) Cut to "Sell" at StockNews.comApril 28, 2023 | americanbankingnews.comInogen (NASDAQ:INGN) Rating Lowered to Sell at StockNews.comApril 27, 2023 | americanbankingnews.comVicarious Surgical (NYSE:RBOT) vs. Inogen (NASDAQ:INGN) Critical AnalysisApril 24, 2023 | americanbankingnews.comInogen (NASDAQ:INGN) Receives "Buy" Rating from Needham & Company LLCApril 18, 2023 | finance.yahoo.comA Look At The Fair Value Of Inogen, Inc. (NASDAQ:INGN)April 13, 2023 | americanbankingnews.comInogen (NASDAQ:INGN) Raised to "Hold" at StockNews.comApril 12, 2023 | americanbankingnews.comInogen (NASDAQ:INGN) and LogicMark (NASDAQ:LGMK) Head to Head ReviewApril 6, 2023 | finance.yahoo.comInogen to Report First Quarter 2023 Financial Results on May 4, 2023April 5, 2023 | americanbankingnews.comInogen (NASDAQ:INGN) Stock Rating Lowered by StockNews.comApril 4, 2023 | finance.yahoo.comInogen to Present at 22nd Annual Needham Virtual Healthcare ConferenceMarch 27, 2023 | finance.yahoo.comAt US$12.41, Is Inogen, Inc. (NASDAQ:INGN) Worth Looking At Closely?March 26, 2023 | americanbankingnews.comInogen (NASDAQ:INGN) Stock Price Passes Below 200-Day Moving Average of $21.40March 22, 2023 | finance.yahoo.comInogen Announces Appointment of Tom West to Board of Directors and Retirement of Board Member Kristen MirandaMarch 22, 2023 | finance.yahoo.comStrength Seen in Inogen (INGN): Can Its 5.0% Jump Turn into More Strength?March 8, 2023 | finance.yahoo.comInogen to Present at KeyBanc Life Sciences & MedTech Investor ForumSee More Headlines INGN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INGN Company Calendar Last Earnings5/04/2023Today6/08/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical appliances & supplies Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:INGN CUSIPN/A CIK1294133 Webwww.inogen.com Phone(805) 562-0500FaxN/AEmployees1,026Year Founded2001Price Target and Rating Average Stock Price Forecast$24.00 High Stock Price Forecast$26.00 Low Stock Price Forecast$22.00 Forecasted Upside/Downside+124.7%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($3.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-83,770,000.00 Net Margins-24.36% Pretax Margin-24.24% Return on Equity-11.06% Return on Assets-8.22% Debt Debt-to-Equity RatioN/A Current Ratio4.47 Quick Ratio3.85 Sales & Book Value Annual Sales$369.02 million Price / Sales0.67 Cash FlowN/A Price / Cash FlowN/A Book Value$12.98 per share Price / Book0.82Miscellaneous Outstanding Shares23,121,000Free Float22,973,000Market Cap$246.93 million OptionableOptionable Beta1.02 Social Links Key ExecutivesNabil ShabshabPresident, Chief Executive Officer & DirectorKristin A. CaltriderChief Financial Officer, Treasurer & EVPStanislav GlezerChief Technology Officer & Executive VPGeorge J. ParrChief Commercial Officer & Executive VPJason SomerSecretary, Executive VP & General CounselKey CompetitorsVicarious SurgicalNYSE:RBOTSanara MedTechNASDAQ:SMTIEargoNASDAQ:EARCollPlant BiotechnologiesNASDAQ:CLGNMilestone ScientificNYSE:MLSSView All CompetitorsInstitutional OwnershipToroso Investments LLCBought 11,301 shares on 5/23/2023Ownership: 0.049%Ameriprise Financial Inc.Sold 336,663 shares on 5/22/2023Ownership: 0.549%JPMorgan Chase & Co.Bought 2,846 shares on 5/18/2023Ownership: 0.172%Rockefeller Capital Management L.P.Bought 246,829 shares on 5/17/2023Ownership: 1.184%Meros Investment Management LPSold 1,793 shares on 5/16/2023Ownership: 1.221%View All Institutional Transactions INGN Stock - Frequently Asked Questions Should I buy or sell Inogen stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" INGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INGN, but not buy additional shares or sell existing shares. View INGN analyst ratings or view top-rated stocks. What is Inogen's stock price forecast for 2023? 3 Wall Street analysts have issued 12-month price objectives for Inogen's shares. Their INGN share price forecasts range from $22.00 to $26.00. On average, they predict the company's stock price to reach $24.00 in the next year. This suggests a possible upside of 115.1% from the stock's current price. View analysts price targets for INGN or view top-rated stocks among Wall Street analysts. How have INGN shares performed in 2023? Inogen's stock was trading at $19.71 on January 1st, 2023. Since then, INGN shares have decreased by 43.4% and is now trading at $11.16. View the best growth stocks for 2023 here. When is Inogen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our INGN earnings forecast. How were Inogen's earnings last quarter? Inogen, Inc. (NASDAQ:INGN) released its quarterly earnings data on Thursday, May, 4th. The medical technology company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.77) by $0.14. The medical technology company earned $72.16 million during the quarter, compared to the consensus estimate of $74.68 million. Inogen had a negative net margin of 24.36% and a negative trailing twelve-month return on equity of 11.06%. The company's quarterly revenue was down 10.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.38) earnings per share. What ETFs hold Inogen's stock? ETFs with the largest weight of Inogen (NASDAQ:INGN) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), Cultivar ETF (CVAR), Syntax Stratified SmallCap ETF (SSLY), Invesco S&P SmallCap Health Care ETF (PSCH), Principal Healthcare Innovators ETF (BTEC), iShares U.S. Medical Devices ETF (IHI), What is Scott Wilkinson's approval rating as Inogen's CEO? 70 employees have rated Inogen Chief Executive Officer Scott Wilkinson on Glassdoor.com. Scott Wilkinson has an approval rating of 46% among the company's employees. This puts Scott Wilkinson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Inogen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), (MDVN) (MDVN), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), First Solar (FSLR), Intel (INTC) and Netflix (NFLX). What is Inogen's stock symbol? Inogen trades on the NASDAQ under the ticker symbol "INGN." Who are Inogen's major shareholders? Inogen's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (17.20%), Brown Capital Management LLC (9.55%), Fred Alger Management LLC (4.86%), State Street Corp (4.65%), Dimensional Fund Advisors LP (3.72%) and Geode Capital Management LLC (1.95%). Insiders that own company stock include Alison Bauerlein, Brenton Taylor, Byron Myers, Holdings A/S Novo, Ray Benjamin M Anderson and Raymond Huggenberger. View institutional ownership trends. How do I buy shares of Inogen? Shares of INGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Inogen's stock price today? One share of INGN stock can currently be purchased for approximately $11.16. How much money does Inogen make? Inogen (NASDAQ:INGN) has a market capitalization of $258.03 million and generates $369.02 million in revenue each year. The medical technology company earns $-83,770,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis. How many employees does Inogen have? The company employs 1,026 workers across the globe. How can I contact Inogen? Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The official website for the company is www.inogen.com. The medical technology company can be reached via phone at (805) 562-0500 or via email at mpigeon@inogen.net. This page (NASDAQ:INGN) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inogen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.